In a pre-Hal­loween fright show, Cel­gene just scared the hell out of Wall Street — shares crater

For years now Cel­gene has im­pressed an­a­lysts and wowed in­vestors with ag­gres­sive rev­enue growth and one of the most am­bi­tious R&D ef­forts in biotech. But af­ter alarm­ing Wall Street with a ma­jor fail for one of its big Phase III drugs a few days ago, Cel­gene man­aged to score a pre-Hal­loween fright that sent its shares — al­ready bad­ly dent­ed by the fail­ure of mon­gersen — tum­bling $CELG 18% Thurs­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER